Evidence map›Paper›PMID 42363834›Full record

ArticleAntimicrobial agents and chemotherapy2026

Gabriela P Dos Santos, Ingrid de O Dias, Suvajit Koley, Marvin J Meyers, Juliana Q Reimão

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gabriela P Dos SantosLaboratory of Preclinical Assays and Research of Alternative Sources of Innovative Therapy for Toxoplasmosis and Other Sicknesses (PARASITTOS), Faculdade de Medicina de Jundiaíi, Jundiaí, São Paulo, Brazil.ORCID 0009-0009-3706-9099
Ingrid de O DiasLaboratory of Preclinical Assays and Research of Alternative Sources of Innovative Therapy for Toxoplasmosis and Other Sicknesses (PARASITTOS), Faculdade de Medicina de Jundiaíi, Jundiaí, São Paulo, Brazil.ORCID 0000-0002-6526-0749
Suvajit KoleyDepartment of Chemistry, Saint Louis University, Saint Louis, Missouri, USA.ORCID 0000-0003-4017-346X
Marvin J MeyersDepartment of Chemistry, Saint Louis University, Saint Louis, Missouri, USA.ORCID 0000-0001-5484-619X
Juliana Q ReimãoLaboratory of Preclinical Assays and Research of Alternative Sources of Innovative Therapy for Toxoplasmosis and Other Sicknesses (PARASITTOS), Faculdade de Medicina de Jundiaíi, Jundiaí, São Paulo, Brazil.ORCID 0000-0002-4418-0838

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2018/18954-4Fundação de Amparo à Pesquisa do Estado de São Paulo 2020/03399-5Fundação de Amparo à Pesquisa do Estado de São Paulo 2024/15691-3Fundação de Amparo à Pesquisa do Estado de São Paulo 2024/22547-6
6 · The paper itself

Abstract

Toxoplasmosis, caused by the protozoan

Indexed as

Antiprotozoal AgentsAspartic Acid ProteasesProtease InhibitorsToxoplasmaToxoplasmosisAnimalsFemaleFibroblastsHumansMiceAntiprotozoal AgentsAspartic Acid ProteasesProtease Inhibitorsaspartic protease inhibitorsin vitromicepreclinical assaystoxoplasmosis

Identifiers

PMID42363834
PMCPMC13435739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.